BAT1706 vs HD204

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

HD204

Developed by Intas Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03390686 · Phase 3 · active, not recruiting

This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.

Reported efficacy

Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)

Result source: NCT03390686

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1706HD204
PFS, median—Not posted · NCT03329911—Trial running · NCT03390686
OS, median—Not posted · NCT03329911—Trial running · NCT03390686
ORR—Not posted · NCT03329911—Trial running · NCT03390686
Duration of response, median—Not posted · NCT03329911—Trial running · NCT03390686

PFS, median

BAT1706
—Not posted · NCT03329911
HD204
—Trial running · NCT03390686

OS, median

BAT1706
—Not posted · NCT03329911
HD204
—Trial running · NCT03390686

ORR

BAT1706
—Not posted · NCT03329911
HD204
—Trial running · NCT03390686

Duration of response, median

BAT1706
—Not posted · NCT03329911
HD204
—Trial running · NCT03390686
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HD204
SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin NCT03390686 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT1706: 3 of 4 rows · HD204: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBAT1706
Dropout rate
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · HD204's landscape